Top Brands Revolutionizing Hepatitis B Vaccines

Hepatitis B is a serious liver infection, and taking the right vaccine is crucial for prevention. With several brands available in the market, it can be challenging to determine which options are the most reliable. Renowned for their effectiveness and safety, certain vaccines stand out among healthcare professionals and patients alike. Each brand offers unique features, ensuring a robust immune response and promising long-term protection. To help you make an informed decision, explore the list of top-rated hepatitis B vaccine brands discussed below.

Illustration of hepatitis b vaccine

Best brands of hepatitis b vaccine in 2025

Engerix-B

Engerix-B, developed by GlaxoSmithKline, is a highly effective hepatitis B vaccine, particularly noted for its long-standing presence in the market since its approval in 1989. Clinical trials have shown that after a 3-dose schedule, Engerix-B achieves a seroprotection rate of 79% at month 6 and 96% at month 7 in healthy adults and adolescents. It is widely used across various age groups and has been a standard in hepatitis B vaccination. Despite its efficacy, Engerix-B faces competition from newer vaccines like Heplisav-B, which offers a shorter 2-dose regimen. Engerix-B remains a reliable choice, especially in populations such as those with chronic hepatitis C, where it has shown 100% response with seroprotective titers.

Recombivax HB

Recombivax HB, manufactured by Merck & Co, Inc, is a highly effective recombinant hepatitis B vaccine, demonstrating an impressive seroprotection rate of 95% in preventing chronic hepatitis B infection in neonates exposed to the virus at birth. In clinical trials, three 5 mcg doses of Recombivax HB induced a protective level of antibody in 100% of infants, 99% of children, and 99% of adolescents. The vaccine has shown significant efficacy, with 96% of infants not developing chronic infection after 9 months of follow-up when combined with hepatitis B immunoglobulin (HBIG). For more in-depth information, visit the FDA's Recombivax HB page.

Heplisav-B

Heplisav-B, developed by Dynavax Technologies Corporation, is a highly effective hepatitis B vaccine, approved by the FDA in 2017 for use in adults. It boasts a superior efficacy rate of 90% to 100% in clinical studies, outperforming other vaccines like Engerix-B, which has an efficacy rate of 70.5% to 90.2%. Heplisav-B is particularly beneficial for individuals with compromised immune systems, such as those with inflammatory bowel disease (IBD), achieving an overall efficacy of 78.3% in this population. The vaccine is administered in a 2-dose regimen and contains the adjuvant CpG 1018 to enhance immune response. As of 2023, Heplisav-B has gained significant market share, with approximately 44% of the U.S. market and 60% in the retail pharmacy segment. For more detailed information, visit the FDA's website about Heplisav-B.

Twinrix

Twinrix, developed by GlaxoSmithKline Biologicals, is a highly effective combined vaccine offering protection against both hepatitis A and hepatitis B. It demonstrates a seroprotection rate against hepatitis B of 92% and 56% at 7 and 48 months, respectively, outperforming some monovalent hepatitis B vaccines. The vaccine achieves seropositivity rates for anti-HAV antibodies of 100% at months 1, 2, and 3 after the initial dose, and nearly all vaccinees have protective titres against hepatitis B one month after completing the vaccination course. Twinrix is well-tolerated and highly immunogenic, making it a convenient and cost-effective option with better compliance rates. Long-term follow-up data shows that over 95% of vaccinees remain protected against hepatitis B at 48 months. For more information, visit the Twinrix product information on the EMA website.

Sci-B-Vac

Sci-B-Vac, developed by VBI Vaccines, stands out as a highly effective hepatitis B vaccine, particularly noted for its rapid onset of seroprotection and high anti-HBs titers. In Phase 3 studies, Sci-B-Vac achieved seroprotection rates (SPR) of 87.2%-100% after two vaccinations, significantly outperforming Engerix-B with SPR rates of 39.0%-89.4%. It induced geometric mean concentrations (GMCs) of anti-HBs titers 6-8 times higher than Engerix-B across various study subgroups, including older adults and those with comorbidities. This vaccine has demonstrated lot-to-lot consistency and high safety profiles, making it a valuable option for hepatitis B prevention, especially in young adults aged 18-45. For more detailed information, you can read the press release on VBI Vaccines' official site.

Dynavax

Dynavax is a leading biopharmaceutical company that has established itself as a premier producer of hepatitis B vaccines, particularly with its flagship product, HEPLISAV-B. As of 2024, HEPLISAV-B controls approximately 44% of the U.S. adult hepatitis B vaccine market, up from 42% at the end of 2023 and 35% in 2022. The vaccine generated $213 million in net revenues in 2023, representing a 69% year-over-year increase, and continues to show strong growth with a 27% increase in Q3 2024 to $79.3 million. HEPLISAV-B's robust market performance is expected to drive substantial revenue growth, with projections indicating the vaccine could achieve at least 60% of the U.S. adult hepatitis B vaccine market, which is expected to exceed $900 million by 2030. This positions Dynavax for significant financial growth and further investment in research and development.

Euvax B

Euvax B, produced by LG Chem, is a highly effective and well-tolerated recombinant hepatitis B vaccine, demonstrating excellent immunogenicity with seroprotection rates of up to 98.6% in universal infant vaccination programs. The vaccine is manufactured using yeast-derived recombinant DNA technology, ensuring no use of human blood products and making it safe for all age groups. It has been used successfully in various countries, including Argentina and Bulgaria, with low reactogenicity and high geometric mean concentrations of anti-HBsAg. Euvax B meets WHO requirements and is administered in a 0-1-6 month schedule, providing robust protection against hepatitis B virus infection. Its safety and efficacy have been documented in multiple clinical trials. For more detailed information, visit the Euvax B information page.

Shanvac-B

Shanvac-B, a recombinant DNA hepatitis B vaccine developed in India, has demonstrated high efficacy and safety in clinical trials. In a study involving 81 healthy volunteers, 53% seroconverted after the first dose, with 26% achieving seroprotection (anti-HBs > 10 mIU/mL). By the third dose, seroprotection rates reached 100%, with geometric mean titres of anti-HBs as high as 2246 mIU/mL. The vaccine was well-tolerated, with only one reported adverse event of an urticarial rash after the second dose. This vaccine is a significant contributor to hepatitis B prevention, especially in regions where access to effective vaccines is crucial. For more detailed information, refer to the study on PubMed.

Supervac-B

Hepatitis B vaccines from brands like Engerix-B and H-B-Vax II, produced using recombinant DNA technology, have proven highly effective, with over 90-95% of vaccine recipients aged under 40 years achieving protective levels of neutralizing antibody against HBV. These vaccines are administered in a standard 3-dose schedule and are available in various formulations, including monovalent and combination vaccines. For instance, Engerix-B and H-B-Vax II have been widely used and recommended by health organizations. The vaccines have undergone extensive characterization and process validation to ensure high product purity and potency. As of recent data, these vaccines continue to play a crucial role in reducing hepatitis B incidence and related mortality. For comprehensive details, refer to the CDC's latest recommendations on hepatitis B vaccines.

Genevac B

GeneVac-B, produced by the Serum Institute of India, is a highly effective recombinant hepatitis B vaccine, demonstrating seroprotection rates of 95.6-100% in adults and 100% in children and adolescents. It is administered in a three-dose regimen, with doses given at birth, one month, and six months, showing no significant difference in immunogenicity and safety compared to other vaccines like Engerix B and Shanvac B. The vaccine is well-tolerated, with common side effects being mild and temporary, such as injection site reactions and fever. GeneVac-B is indicated for active immunization against hepatitis B virus (HBV) infection in subjects at risk of exposure, reducing the incidence of HBV infection and its chronic complications. For more details, visit the Serum Institute's dedicated product page.